137 related articles for article (PubMed ID: 16706964)
1. Parachutes and prophylaxis: they both work!
White GC
J Thromb Haemost; 2006 Jun; 4(6):1226-7. PubMed ID: 16706964
[No Abstract] [Full Text] [Related]
2. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
den Uijl IE; Fischer K
Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
[No Abstract] [Full Text] [Related]
3. To bleed or not to bleed - is that a question?
Aledort LM
J Thromb Haemost; 2010 Jan; 8(1):81-2. PubMed ID: 19874456
[No Abstract] [Full Text] [Related]
4. Use of prophylaxis to prevent complications of hemophilia.
Mannucci PM; Mendolicchio L; Gringeri A
Adv Exp Med Biol; 2001; 489():59-64. PubMed ID: 11554591
[No Abstract] [Full Text] [Related]
5. Evidence for the benefits of prophylaxis in the management of hemophilia A.
Hoots WK; Nugent DJ
Thromb Haemost; 2006 Oct; 96(4):433-40. PubMed ID: 17003919
[TBL] [Abstract][Full Text] [Related]
6. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
Feldman BM; Pai M; Rivard GE; Israels S; Poon MC; Demers C; Robinson S; Luke KH; Wu JK; Gill K; Lillicrap D; Babyn P; McLimont M; Blanchette VS;
J Thromb Haemost; 2006 Jun; 4(6):1228-36. PubMed ID: 16706965
[TBL] [Abstract][Full Text] [Related]
7. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
Lowe GD
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
[TBL] [Abstract][Full Text] [Related]
8. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis for hemophilia: state of the art or state of confusion?
Gruppo RA
J Pediatr; 1998 Jun; 132(6):915-7. PubMed ID: 9627577
[No Abstract] [Full Text] [Related]
10. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
[TBL] [Abstract][Full Text] [Related]
11. Haemophilia prophylaxis: a model and future directions in Jordan.
Awidi A; Faouri S; Kiswani BA; Al-Sweedan S; Albarqawi M; Bsoul N; Haddadin I; Al-Falah M; Telfah A; Hermans C
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s343-4. PubMed ID: 24120588
[No Abstract] [Full Text] [Related]
12. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study.
Hilliard P; Zourikian N; Blanchette V; Chan A; Elliott B; Israels SJ; Nilson J; Poon MC; Laferriere N; Van Neste C; Jarock C; Wu J; McLimont M; Feldman B
J Thromb Haemost; 2013 Mar; 11(3):460-6. PubMed ID: 23301594
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic treatment effects on inhibitor risk: experience in one centre.
Morado M; Villar A; Jiménez Yuste V; Quintana M; Hernandez Navarro F
Haemophilia; 2005 Mar; 11(2):79-83. PubMed ID: 15810907
[TBL] [Abstract][Full Text] [Related]
14. Arthropathy and substitution therapy.
Aledort LM
Haemostasis; 1992; 22(5):245-6. PubMed ID: 1478534
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
[TBL] [Abstract][Full Text] [Related]
17. [Hemophilia and the surgical treatment of pathology of the musculoskeletal system].
Chantseva EA; Kuz'minykh AP
Ortop Travmatol Protez; 1990 Mar; (3):49-52. PubMed ID: 2114601
[No Abstract] [Full Text] [Related]
18. Low doses of factor VIII for selected ankle bleeds in severe haemophilia A.
Aronstam A; Wassef M; Hamad Z
Br Med J (Clin Res Ed); 1982 Mar; 284(6318):790. PubMed ID: 6802229
[No Abstract] [Full Text] [Related]
19. [A protocol for the orthopaedic prophylaxis in the rehabilitation of haemarthrosis in haemophilia A ].
Aznar JA; Miranda L; Espinosa C; Querol F; Martín G; Marty ML
Sangre (Barc); 1982; 27(2):156-64. PubMed ID: 6812226
[No Abstract] [Full Text] [Related]
20. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Manco-Johnson MJ; Abshire TC; Shapiro AD; Riske B; Hacker MR; Kilcoyne R; Ingram JD; Manco-Johnson ML; Funk S; Jacobson L; Valentino LA; Hoots WK; Buchanan GR; DiMichele D; Recht M; Brown D; Leissinger C; Bleak S; Cohen A; Mathew P; Matsunaga A; Medeiros D; Nugent D; Thomas GA; Thompson AA; McRedmond K; Soucie JM; Austin H; Evatt BL
N Engl J Med; 2007 Aug; 357(6):535-44. PubMed ID: 17687129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
